Search clinical trials for: PF-06751979 multiple dose

Total 209 results

Pfizer

Completed

Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.

Healthy Subjects

Belgium
Pfizer

Completed

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Healthy Subjects

United States
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG2222

Healthy

Belgium
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Healthy

United States
Enterprise Therapeutics Ltd

Completed

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

Cystic Fibrosis

United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants

Healthy

Belgium
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

Safety, Tolerability and Pharmacokinetics of FTP-198 in Healthy Australian Volunteers

Healthy

Australia
Pfizer

Active, not recruiting

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

Healthy

United States
GEN İlaç ve Sağlık Ürünleri A.Ş.
Sulfateq B.V.

Recruiting

A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects

Healthy Subjects

Turkey
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1837

Healthy

Belgium
Novartis Pharmaceuticals

Completed

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

Schizophrenia Disorders

United States
Galapagos NV

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects

Healthy

Belgium
Chinook Therapeutics, Inc.

Active, not recruiting

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

IgA Nephropathy

Korea, Republic of, United States, United Kingdom
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1972

Healthy

Belgium
Pfizer

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Galapagos NV

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.

Healthy

Belgium
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

Idiopathic Pulmonary Fibrosis

United States
Pfizer

Completed

A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis

Colitis, Ulcerative

Spain, Belgium, Germany, Czech Republic, Norway, Denmark, Slovakia
Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

Ulcerative Colitis

United States
Pfizer

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
J2H Biotech

Completed

Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males

Non-alcoholic Steatohepatitis

Korea, Republic of
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Pharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707

France
Emerald Health Pharmaceuticals

Completed

To Evaluate the Safety and Tolerability, Pharmacokinetics, Food-effect and Pharmacodynamics of EHP-101 in Healthy Volunteers

Healthy

Australia
Pfizer

Completed

PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)

Alopecia Areata

China, United States, Spain, Korea, Republic of, Taiwan, Canada, Australia, Germany, Czechia, Poland, Hungary, Japan, United Kingdom, Argentina, Chile, Colombia, Mexico, Russian Federation
Arthrosi Therapeutics
Iqvia Pty Ltd

Completed

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

Renal Impairment

United States, New Zealand
Pfizer

Completed

Study in Healthy Adults Evaluating PF-07202954

Liver Fibrosis | Non-Alcoholic Fatty Liver Disease

United States
Pfizer

Completed

A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

Type 2 Diabetes Mellitus

Japan
MicuRx
Worldwide Clinical Trials

Completed

Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4

Safety
Longbio Pharma

Active, not recruiting

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

Chronic Spontaneous Urticaria

China
Pfizer

Completed

A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease

Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | COPD | Chronic Obstructive Airway Disease

Germany
Pfizer

Completed

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Longbio Pharma

Recruiting

A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants

Paroxysmal Nocturnal Hemoglobinuria (PNH)

China
Kind Pharmaceuticals LLC

Completed

A Dose-escalation Study of AND017 in Healthy Subjects

Healthy Volunteers

Australia
Curacle Co., Ltd.
KCRN Research, LLC

Completed

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

Diabetic Macular Edema

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Healthy Participants

Germany
Waterstone Pharmaceutical (Wuhan) Co., LTD.

Completed

The Safety and Tolerability of WS016 in Healthy Chinese Volunteers

Hyperkalemia

China
Galapagos NV

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

Healthy

Netherlands
Pfizer
Trans Tech Pharmaceuticals

Completed

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Alzheimer Disease

United States
GangaGen, Inc.

Completed

Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients

Bacterial Infections | Infectious Disease

Singapore
Menarini Group

Completed

Oral Treatment for Orthopaedic Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride (DAVID-art)

Acute Pain

Serbia, Latvia, Spain, Hungary, Lithuania, Poland, Taiwan, Czech Republic, Germany, Ukraine
Pfizer

Completed

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Hypercholesterolemia

United States
Menarini Group

Completed

Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride (DAVID lap)

Acute Pain

Romania, Poland, Hungary, Latvia, Lithuania, Russian Federation, Slovakia, Spain
Longbio Pharma

Active, not recruiting

A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects

Myelodysplastic Syndrome (MDS)

China
Ablynx

Completed

Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.

Healthy Volunteers

United States
Pfizer

Withdrawn

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

Healthy

United States
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001 (CHF6001Ext)

Chronic Obstructive Pulmonary Disease

United Kingdom
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany

3

Subscribe